Neuromarketing Applied to Education. Analysis of face-to-face versus online teaching

[EN] The use of new technologies applied to e-learning has created a few issues related to the attention, as well as the improvement (or the lack) of learning. Thanks to the knowledge and technologies applied in neuromarketing, it has been proven that the levels of attention and commitment to learning, as well as the emotional intensity felt, are greater in a face-to-face classroom compared to a deferred broadcast of a class. Therefore, all this reconsiders a new field of study where distance education can be as effective as face-to-face education.[ES] El uso de las nuevas tecnologías aplicadas a la educación a distancia ha generado una serie de interrogantes respecto a la atención, así como el mejoramiento o no del aprendizaje. Gracias a los conocimientos y tecnologías aplicados en neuromarketing, se ha comprobado que los niveles de atención y compromiso con el aprendizaje, así como la intensidad emocional sentida, son mayores en un aula presencial frente a una retransmisión de una clase en diferido. Por lo que todo esto replantea un nuevo campo de estudio donde la educación a distancia pueda ser tan efectiva como la presencial.Bellido García, I.; Lomello, M.; Serrano Agudelo, D.; Olarte Valencia, MS.; Pérez Micharet, P.; Larios De Medrano Gutiérrez, A.; Gil Escobedo, J.... (2022). Neuromarketing Aplicado a la Educación. Análisis de la enseñanza presencial versus la enseñanza online. Editorial Universitat Politècnica de València. 1359-1373. https://doi.org/10.4995/INRED2022.2022.159171359137

Plan de contingencia para los servicios de medicina intensiva frente a la pandemia COVID-19

In January 2020, the Chinese authorities identified a new virus of the Coronaviridae family as the cause of several cases of pneumonia of unknown aetiology. The outbreak was initially confined to Wuhan City, but then spread outside Chinese borders. On 31 January 2020, the first case was declared in Spain. On 11 March 2020, The World Health Organization (WHO) declared the coronavirus outbreak a pandemic. On 16 March 2020, there were 139 countries affected. In this situation, the Scientific Societies SEMICYUC and SEEIUC, have decided to draw up this Contingency Plan to guide the response of the Intensive Care Services. The objectives of this plan are to estimate the magnitude of the problem and identify the necessary human and material resources. This is to provide the Spanish Intensive Medicine Services with a tool to programme optimal response strategies

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio